← Back to Search

Monoclonal Antibodies

Bevacizumab for Breast Cancer

Phase 2
Waitlist Available
Led By Clinton Yam
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Study Summary

This trial is studying a combination of drugs as a possible treatment for triple-negative breast cancer.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
RCB Status
Secondary outcome measures
Biomarkers of response
Incidence of toxicity
Interaction of treatment and each signature
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (DAE)Experimental Treatment4 Interventions
Patients receive pegylated liposomal doxorubicin hydrochloride IV over about 3 hours on day 1, bevacizumab IV over 90 minutes on day 1, and everolimus PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients will not receive bevacizumab during cycle 4 of therapy. Patients then undergo surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab
2013
Completed Phase 4
~5280
Pegylated Liposomal Doxorubicin Hydrochloride
2001
Completed Phase 3
~4520
Everolimus
2010
Completed Phase 4
~1510

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,958 Previous Clinical Trials
1,798,252 Total Patients Enrolled
148 Trials studying Breast Cancer
63,286 Patients Enrolled for Breast Cancer
Clinton YamPrincipal InvestigatorM.D. Anderson Cancer Center
6 Previous Clinical Trials
1,213 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential complications are associated with the administration of Bevacizumab?

"While there is some evidence of Bevacizumab's safety, no studies have yet confirmed its efficacy. Thus, our team has rated it a 2 on the scale from 1 to 3."

Answered by AI

To what medical conditions is Bevacizumab regularly prescribed?

"Bevacizumab is commonly prescribed to treat recurrent platinum drug resistant primary peritoneal cancer, and can also be used in the management of other illnesses such as neoplasm metastasis, recurrent non-squamous non-small cell lung cancer, neuroendocrine tumors."

Answered by AI

Have any other experiments been conducted using Bevacizumab as a treatment?

"Bevacizumab is presently being tested in 800 trials, 223 of which are currently at Phase 3. Most clinical tests for Bevacizumab occur in Bethesda, Maryland; however altogether there exist 42271 locations running studies with this therapeutic agent."

Answered by AI

Are recruitment efforts still underway for this research project?

"Data hosted on clinicaltrials.gov affirms that this trial is not currently employing new patients; the study was initially published on December 1st, 2016 and last amended on August 18th 2022. However, there are 5358 other medical studies presently enrolling participants."

Answered by AI

Is this endeavor a novel approach to the issue?

"Research into bevacizumab began in 1997 with a study sponsored by Alfacell, involving 300 participants. Subsequent Phase 3 approval was granted and there are now 800 extant experiments being conducted across 2588 cities and 74 countries worldwide."

Answered by AI

How many individuals have been accepted into this experiment?

"Unfortunately, this clinical trial is no longer enrolling patients. It was initially posted on December 1st 2016 and last updated in August 18th 2022. If you are considering other medical trials, there are currently 4558 studies actively recruiting for carcinoma treatments as well as 800 trials using bevacizumab recruiting participants."

Answered by AI
~2 spots leftby Mar 2025